- Report
- October 2024
- 98 Pages
Global
From €3500EUR$4,093USD£3,079GBP
- Report
- August 2024
- 73 Pages
Global
From €3500EUR$4,093USD£3,079GBP
- Report
- February 2024
- 108 Pages
Global
From €3500EUR$4,093USD£3,079GBP
- Report
- July 2022
- 98 Pages
Global
From €3500EUR$4,093USD£3,079GBP
- Report
- November 2022
- 99 Pages
Global
From €1832EUR$2,000USD£1,557GBP
- Report
- September 2022
- 57 Pages
Global
From €1832EUR$2,000USD£1,557GBP
- Report
- September 2022
- 70 Pages
Global
From €1832EUR$2,000USD£1,557GBP
- Report
- May 2022
- 51 Pages
Global
From €1832EUR$2,000USD£1,557GBP
- Report
- May 2022
- 210 Pages
Global
From €2290EUR$2,500USD£1,946GBP
- Report
- March 2025
- 145 Pages
China
From €1649EUR$1,800USD£1,401GBP
- Report
- March 2025
- 89 Pages
China
From €1649EUR$1,800USD£1,401GBP
- Report
- January 2025
- 132 Pages
Global
From €870EUR$950USD£740GBP
- Report
- May 2023
- 249 Pages
Global
From €2289EUR$2,499USD£1,946GBP
€3270EUR$3,570USD£2,779GBP
- Book
- March 2020
North America

The Anemia Drug market is a subset of the larger Hematological Drugs market, which includes drugs used to treat blood-related diseases. Anemia drugs are used to treat anemia, a condition in which the body does not produce enough healthy red blood cells. These drugs can be used to treat a variety of anemias, including iron deficiency anemia, aplastic anemia, and sickle cell anemia. Anemia drugs can be administered orally, intravenously, or intramuscularly, depending on the type of anemia being treated.
Common anemia drugs include erythropoietin, darbepoetin, and epoetin alfa. Erythropoietin is a hormone that stimulates the production of red blood cells, while darbepoetin and epoetin alfa are synthetic versions of erythropoietin. Other anemia drugs include iron supplements, folic acid, and vitamin B12.
Some companies in the Anemia Drug market include Amgen, Johnson & Johnson, Novartis, Pfizer, and Roche. Show Less Read more